Microbleeds found in the brains of people with Parkinson’s disease by magnetic resonance imaging (MRI) scans were associated with cognitive decline, a study demonstrated.  Higher levels of a microbleed-associated biomarker also were found in patients with dementia. Moreover, a statistical analysis found the…

Parkinson’s UK has opened a survey aimed at understanding the experiences of caregivers of people who have Lewy body dementia or Parkinson’s disease dementia. The survey seeks to shed light on the support caregivers receive, and caregivers’ and patients’ experiences with the health and social care system in…

People with a sleep disorder marked by the physical “acting out” of vivid dreams — a condition considered an early form of  Parkinson’s disease — show changes in specific immune cells in the blood that directly relate to inflammation and damage to dopamine neurons in the brain, researchers…

Sesaminol, a waste product of sesame oil production with antioxidant properties that might protect nerve cells, was found to prevent some symptoms of Parkinson’s disease in a mouse model in a recent study. Treated mice, its researchers reported, showed better balance and fewer gastrointestinal issues than mice in this…

Scientists at Cognition Therapeutics have found that compounds that are able to dampen the activity of sigma-2 receptors — receptors that are part of a network that controls the destruction of misfolded proteins — are highly effective at preventing molecule trafficking defects driven by the presence of misfolded alpha-synuclein inside…

The levels of a specific RNA molecule that provides instructions to make the alpha-synuclein protein may help, at an early stage, to distinguish patients with Parkinson’s disease from those with dementia with Lewy bodies, a study has found. Researchers said these results highlight the importance of exploring the potential…

Treatment with the antioxidant metal-alloy nanozyme reduced the build-up (aggregation) and transmission of disease-causing alpha-synuclein protein in the nerve cells and brains of a Parkinson’s disease mouse model, a study reported. Investigators believe these findings support further research to evaluate nanozymes as a Parkinson’s treatment.

Researchers have developed a faster method of measuring the rate at which alpha-synuclein protein forms toxic clumps that reliably distinguishes people with Parkinson’s disease from those without the condition. The findings support the use of this test — which cuts by more than half the time required to obtain…

Delivering an alpha-synuclein-targeting molecule, called ASO4, in tiny fatty vesicles reduced toxic alpha-synuclein clumps and dopaminergic neuron loss — two main hallmarks of Parkinson’s disease — and lessened motor impairments in a mouse model of the disease. Results of the study add to previous findings suggesting that these…

Eisai is partnering with Wren Therapeutics to advance the discovery of new small molecule compounds capable of reducing the misfolding and aggregation of alpha-synuclein, the underlying cause of different neurological disorders, including Parkinson’s disease and dementia with Lewy bodies. The research collaboration will leverage Wren’s…